JIP
ALXN

Jaffetilchin Investment Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Jaffetilchin Investment Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,344
Closed -$434K – 249
2014
Q4 		$434K Buy
+2,344
New +$434K 0.15% 103
2014
Q2 		– Sell
-2,183
Closed -$332K – 245
2014
Q1 		$332K Sell
2,183
-497
-19% -$79K 0.13% 135
2013
Q4 		$356K Buy
+2,680
New +$322K 0.18% 104

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jaffetilchin Investment Partners's ALXN Position: Q1 2015 in Review

Jaffetilchin Investment Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2015, closing a stake of 2,344 shares — an estimated $434K sold.

Jaffetilchin Investment Partners first reported a position in ALXN in Q4 2013 and held it in 3 quarters. The position peaked at $434K in Q4 2014. 566 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

  • Jaffetilchin Investment Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 2,344 Alexion Pharmaceuticals shares in Q1 2015, an estimated $434K.
  • Jaffetilchin Investment Partners first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Jaffetilchin Investment Partners's Alexion Pharmaceuticals position peaked at $434K in Q4 2014.
  • 566 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on Jaffetilchin Investment Partners's 13F filing for Q1 2015, filed 1 May 2015.